About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to Editor

1. T​he report 'Comparator report on patient access to cancer medicines in Europe revisited – a UK perspective' was commissioned and funded by the ABPI. Research was carried out by the Institute of Health Economics. It is available via the ABPI website here. To cite this report, please use:

Jönsson B, Hofmarcher T, Lindgren P, Moen F & Wilking N. Comparator report on patient access to cancer medicines in Europe revisited – A UK perspective. IHE Report 2017:1, IHE: Lund, Sweden.
 

The cancer comparator toolkit can be found online here.​​

​2. The ten cancer compared for survival rates are:  breast cancer, lung cancer, bowel cancer, prostate cancer, malignant melanoma, Pancreatic cancer, ovarian cancer and aematological cancers (leukaemia, Hodgkin's lymphoma, Non-Hodgkin lymphoma)

3. Six cancer medicines compared:  trastuzumab, imatinib, bevacizumab, erlotinib, ipulimumab and lenalidomide

References

 

[1] IHE UK Report Page 33 (IMS Health MiDAS Database)

[2] Jönsson et al., Comparator Report on Patient Access to Cancer Medicines in Europe Revisited - a UK Perspective. Institute for Health Economics 2017

[3] Jönsson et al., Comparator Report on Patient Access to Cancer Medicines in Europe Revisited - a UK Perspective. Institute for Health Economics 2017

[4] IHE UK Report Page 21 (De Angelis, R., et al., Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE 5 a population based study. Lancet Oncology, 2014)

[5] IHE UK Report Figure 1 (European Cancer Observatory) & Figure 10 (Eurocare 3-5)

[6] IHE UK Report Figure 7 (European Cancer Observatory)

[7] IHE UK Report

[8] IHE UK Report Page 45/37 (IMS Health MiDAS Database)​

Media enquiries


+44 (0) 20 7747 7147​​